In the BELT crossover trial, 3 g/day high-viscosity oat beta-glucan lowered LDL cholesterol over 8 weeks in adults with mild hypercholesterolemia.

Objective

To assess the medium-term effects of 3 g/day oat beta-glucan on fasting lipid profile, fasting plasma glucose, and self-perceived intestinal well-being in adults with mild to moderate hypercholesterolemia and low cardiovascular risk.

Methods

Double-blind, placebo-controlled, randomized cross-over clinical trial in Italy (BELT Study), conducted in Bologna. After a 4-week Mediterranean-diet run-in, 83 adults (approximately 20–65 years) with moderate hypercholesterolemia and low 10-year CVD risk were randomized to one of two sequences: 8 weeks of oat beta-glucan (3 g/day) or 8 weeks of an isocaloric oat-based placebo without beta-glucan, separated by a 4-week washout, then crossed over to the alternate arm. The beta-glucan was delivered as one daily water-dissolved sachet containing 3 g high–molecular weight, high-viscosity oat beta-glucan (OatWell™-based; very high MW reported as >2,000 kDa). Primary endpoint was change in LDL-C at 4 and 8 weeks. Key secondary endpoints included total cholesterol, non-HDL cholesterol, HDL-C, triglycerides, apolipoproteins (ApoA1, ApoB), fasting plasma glucose, and an intestinal function/well-being questionnaire. Diet records and sachet counts were used to monitor stability and compliance; safety monitoring included clinical/laboratory assessments and adverse event reporting.

Results

Primary outcome (LDL-C):

• LDL-C decreased with beta-glucan by 12.2% at 4 weeks and 15.1% at 8 weeks versus baseline, and these reductions were reported as significant versus placebo.

Secondary outcomes (lipids and glucose):

• Total cholesterol decreased by 6.5% at 4 weeks and 8.9% at 8 weeks versus baseline, significant versus placebo.
• Non-HDL cholesterol decreased by 11.8% at 4 weeks and 12.1% at 8 weeks, significant versus placebo.
• HDL-C, triglycerides, ApoA1, and ApoB showed no significant differences between beta-glucan and placebo periods.
• Fasting plasma glucose was unchanged.

Durability and tolerability:

• Lipid values returned toward baseline within about 2 weeks after stopping beta-glucan during washout.
• Compliance was about 89%.
• Adverse events included moderate abdominal discomfort (reversible cramps/diarrhea) in three participants and dysphagia in one participant during the beta-glucan period; no laboratory safety signals and no discontinuations due to adverse events were reported.
• Self-reported intestinal well-being did not differ significantly between beta-glucan and placebo periods.

Interpretation

In this low-risk adult population adhering to a Mediterranean-style diet, 3 g/day of high–molecular weight, high-viscosity oat beta-glucan was associated with clinically meaningful reductions in LDL-C, total cholesterol, and non-HDL cholesterol over 8 weeks, without changes in fasting glucose or overall self-reported intestinal well-being. The lipid-lowering effect appeared dependent on ongoing intake, as levels reverted toward baseline after discontinuation.

Mechanisms Discussed by Authors

The authors attribute lipid lowering primarily to viscosity-driven intestinal effects, including reduced bile-acid and cholesterol uptake and increased fecal loss, which may stimulate hepatic conversion of cholesterol to bile acids (e.g., via increased bile-acid synthesis pathways). They emphasize that higher molecular weight and viscosity are associated with greater lipid effects. Additional hypotheses such as microbiota-related effects were discussed but not directly measured.

Dosage and Safety

Dose and formulation were 3 g/day oat beta-glucan delivered as a water-dissolved daily sachet for 8 weeks per treatment period (high molecular weight, high viscosity). Reported adverse events during beta-glucan included transient abdominal cramps/diarrhea in three participants and one case of dysphagia; no laboratory safety concerns and no discontinuations due to adverse events were described.

Study Quality

Strengths include a randomized, double-blind cross-over design; diet stabilization with monitoring; prespecified lipid endpoints; and use of a characterized high–molecular weight/high-viscosity beta-glucan product. Limitations include medium-term duration only, reliance on calculated LDL-C (Friedewald) rather than direct measurement, limited generalizability beyond a Mediterranean-diet low-risk cohort, and lack of mechanistic measurements (e.g., bile acids, fecal sterols, microbiome/SCFAs, in vivo viscosity effects).

Implications

This trial adds controlled evidence that 3 g/day of a high-viscosity oat beta-glucan preparation can lower LDL-C within weeks in mildly hypercholesterolemic adults, with effects that diminish after stopping intake. Longer and more mechanistically informative studies are needed to confirm durability, clarify mechanisms, and assess broader populations.